NCT00902564

Escitalopram in Patients With Generalized Anxiety Disorder

Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.

Detailed description

The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The patients will receive escitalopram for 8 weeks. Start and maintenance dosages as well as dose titration will be left to the investigators' decision (5 to 20 mg/day), in accordance with the national Summary of Products Characteristics (SPC).

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Escitalopram	Flexible-dosed (5 to 20 mg Oral Tablets Daily)

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-12-01
• Completion: 2010-03-01
• First posted: 2009-05-15
• Last updated: 2011-06-10
• Results posted: 2011-06-10

Locations

1 site across 1 country: Russia